

# News Releases

All Years

Search

Go

[Advanced Search](#)

**MAY 21, 2019**

**Inhibrx Announces \$40M Investment from Viking Global Investors**

**FEB 19, 2019**

**Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-105, a Novel Multispecific PD-L1 and 4-1BB Antibody**

**JAN 7, 2019**

**bluebird bio and Inhibrx Announce Collaboration to Research, Develop and Commercialize CAR T Cell Immunotherapies**

**DEC 6, 2018**

**Inhibrx Announces Dosing of First Patients in Phase 1 Dose-Escalation Study of INBRX-109, a Novel Multivalent Agonist of Death Receptor 5 (DR5)**

**OCT 31, 2017**


**Inhibrx Wins CARB-X Award Of Up To \$6.0M To Accelerate Development Of Its Novel Antibody, INBRX-111, To Treat Pseudomonas Infections**

**SEP 15, 2015**

**Inhibrx and The Alpha-1 Project Collaborate to Develop a Recombinant Alpha-1 Antitrypsin with Improved Properties**

**JUN 27, 2012**

**Inhibrx announces an Option & License Agreement with Celgene Corporation for Inhibrx Antibody Program**

Show 10  per page

 [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) 



<https://inhibrx.investorroom.com/news-releases?l=10&o=70>